Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + MG4101
- Development stage
- Unknown
- Lead developer
- GC Cell
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Subcutaneous
01
Overview
Rituximab + MG4101 is a combination therapy that pairs rituximab (an anti-CD20 monoclonal antibody) with MG4101, an ex vivo-expanded allogeneic natural killer (NK) cell therapy. This combination is designed to enhance rituximab's antibody-dependent cytotoxicity in relapsed/refractory B-cell non-Hodgkin lymphoma. The treatment regimen typically includes lymphodepletion with fludarabine and cyclophosphamide before rituximab administration, followed by MG4101 infusion and subcutaneous IL-2 administration. Clinical studies have shown a favorable safety profile with mostly grade 1-2 adverse events and promising efficacy with an overall response rate of 55.6% in relapsed/refractory NHL patients.
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on rituximab + MG4101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + MG4101.